Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIPLAR: Efficacy and Safety of Fluticasone/Formoterol/Glycopyrronium in COPD
NCT06234345Phase 3Not yet recruiting
- Sponsor
- Eurofarma
- Start
- Jan 2027
- Primary completion
- Aug 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluticasone propionate nasal spray, formoterol and glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Eurofarma. Primary endpoint: Forced Expiratory Volume in the first second at 12 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
fluticasone propionate nasal sprayformoterolglycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06234345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06234345.